



## modified FOLFOX-6 - Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, colon carcinoma adjuvant

Protocol-ID: 644 V1.1 (Short), mFOLFOX-6 (OXAL85/CFOL400/FU2400), Colon Ca, adj.

### Indication(s)

- Colon Cancer; ICD-10 C18.0, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C19

### Protocol classification

- Classification: current standard
- Intensity: Standard dose
- Therapy phase:
- Therapy intention: curative

### Cycles

Cycle length 14 days, recommended cycles: 12

### Risks

- Emetogenicity (MASCC/ESMO): moderate (30-90%)
- Neutropenia: high (21-40%)
- Febrile Neutropenia: low (<10%)
- Thrombocytopenia below 50 000/ $\mu$ l: low (<10%) °3-4: 3.4%
- Diarrhea: CTC AE °3-4: 9.7%
- Fatigue: CTC AE °3-4: 7.2%
- Thromboembolic Event: CTC AE °3-4: 4.6%
- Neuropathy: CTC AE °3-4: 14.4%, sensory
- Dehydration: CTC AE °3-4: 4.0%
- Allergic Reaction: CTC AE °3-4: 4.7%
- Pain: CTC AE °3-4: 6.3%

### Therapy

#### Hydration: Balanced Crystalloid Solution

HYD

Access: peripheral venous

Hydration before, during, or after antitumor therapy

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
1	Balanced Crystalloid Solution	500 ml		i.v.	60 min	60 min before Oxaliplatin (d1)

**Antiemesis: Emetogenicity moderate, GRAN i.v., DEXA i.v.**

AE

Access: peripheral venous

ASCO 2015, DGHO 2016, DKG 2016, MASCC/ESMO 2016, if palonosetron not available

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
1	<b>Dexamethasone</b>	8 mg	NaCl 0.9% 50 ml	i.v.	5 min	30 min before Oxaliplatin (d1)
1	<b>Granisetron</b>	1 mg	NaCl 0.9% 50 ml	i.v.	5 min	15 min before Oxaliplatin (d1)
or other 5-HT3 receptor antagonist						
2-3	<b>Dexamethasone</b>	8 mg		p.o.		1-0-0-0

**Antineoplastic therapy: mFOLFOX6**

CTX

Access: central venous, port

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
1	<b>Oxaliplatin</b>	85 mg/m <sup>2</sup> BSA	Dextrose 5% 500 ml	i.v.	2 h	Sequence
1	<b>Folinic acid</b>	400 mg/m <sup>2</sup> BSA	NaCl 0.9% 250 ml	i.v.	2 h	Sequence
1	<b>Fluorouracil</b>	400 mg/m <sup>2</sup> BSA	none	i.v.	1 min	Sequence
Bolus application						
1	<b>Fluorouracil</b>	2400 mg/m <sup>2</sup> BSA	NaCl 0.9% 500 ml	i.v.	46 h	Sequence

The volume of the carrier solution refers to inpatient therapy with infusion pumps. When using syringe pumps or ambulatory systems, a different volume (e.g. 100 ml) can be used.

**References**

- Allegra CJ, Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009 Jul 10;27(20):3385-90. doi: 10.1200/JCO.2009.21.9220. PMID: 19414665. [PMID]
- Allegra CJ, Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011 Jan 01;29(1):11-6. doi: 10.1200/JCO.2010.30.0855. PMID: 20940184. [PMID]

**Recommendations**

- 07/2020: [European Society for Medical Oncology](#)
- 11/2023: [National Comprehensive Cancer Network](#)



The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 04.01.2024